We're in the "competitive advantage" business.
Inhalation technology that helps put you in front, faster.
Because it is target specific, inhalation drug delivery has fundamental advantages for therapy of diseases of the respiratory tract, including asthma and Chronic Obstructive Pulmonary Disease. Drugs administered by inhalation minimize systemic absorption and adverse effects compared with drugs that must travel through the gastrointestinal tract.
This growing market continues to evolve as new developments expand this delivery route to larger molecules, such as proteins and peptides. Combined with its clear benefits, inhalation is poised to become the delivery route of choice for a wide variety of inhaled therapies, for both local and systemic drug delivery. MLPL Drug Delivery Systems is a leader in inhalation technology. More than just systems and components, MLPL delivers the expertise, efficiency and flexibility you need to gain a competitive advantage. We partner with you to resolve your formulation challenges, differentiate your pMDI products with optimized components, guide you through regulatory approval and meet worldwide production and supply needs.
- Ability to solve unique formulation challenges
- Unique components to protect and differentiate your pMDI product
- Unsurpassed support throughout the development process, including regulatory filings
- Flexible vertical integration in production and manufacturing saves time and money
- Worldwide production capabilities that meet rigorous global standards
